Jeffrey W Corbett

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists
    Jeffrey W Corbett
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:6250-6. 2007
  2. ncbi request reprint Inhibitors of mammalian acetyl-CoA carboxylase
    Jeffrey W Corbett
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Recent Pat Cardiovasc Drug Discov 2:162-80. 2007
  3. pmc Structure-guided inhibitor design for human acetyl-coenzyme A carboxylase by interspecies active site conversion
    Francis Rajamohan
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    J Biol Chem 286:41510-9. 2011
  4. doi request reprint Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase
    Kevin D Freeman-Cook
    Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
    J Med Chem 55:935-42. 2012
  5. doi request reprint Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes
    Michael P Deninno
    Pfizer Global Research and Development Groton Laboratories, Groton, CT 06340, USA
    Bioorg Med Chem Lett 22:5721-6. 2012
  6. doi request reprint Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2
    Jeffrey W Corbett
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 20:2383-8. 2010
  7. ncbi request reprint Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1
    Jeffrey W Corbett
    DuPont Pharmaceuticals Company, Experimental Station, P O Box 80500, Wilmington, DE 19880 0500, USA
    Prog Med Chem 40:63-105. 2002

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists
    Jeffrey W Corbett
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 17:6250-6. 2007
    ..The most potent indanylpyrazine had a K(i)=11+/-1 nM. The oxygen-linked pyrazinyl derivatives were prepared through a copper-catalyzed coupling of a pyridinone to a bromo- or iodopyrazine...
  2. ncbi request reprint Inhibitors of mammalian acetyl-CoA carboxylase
    Jeffrey W Corbett
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Recent Pat Cardiovasc Drug Discov 2:162-80. 2007
    ..However, demonstration of the full potential of isozyme-selective inhibitors, once identified, should reveal advantages and liabilities associated with single isozyme inhibition...
  3. pmc Structure-guided inhibitor design for human acetyl-coenzyme A carboxylase by interspecies active site conversion
    Francis Rajamohan
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    J Biol Chem 286:41510-9. 2011
    ..These structures offer insights that explain the species selectivity of ACC inhibitors and may guide future drug design programs...
  4. doi request reprint Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase
    Kevin D Freeman-Cook
    Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
    J Med Chem 55:935-42. 2012
    ..Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies...
  5. doi request reprint Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes
    Michael P Deninno
    Pfizer Global Research and Development Groton Laboratories, Groton, CT 06340, USA
    Bioorg Med Chem Lett 22:5721-6. 2012
    ..These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development...
  6. doi request reprint Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2
    Jeffrey W Corbett
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 20:2383-8. 2010
    ..Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype...
  7. ncbi request reprint Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1
    Jeffrey W Corbett
    DuPont Pharmaceuticals Company, Experimental Station, P O Box 80500, Wilmington, DE 19880 0500, USA
    Prog Med Chem 40:63-105. 2002
    ..This chapter reviews the discovery and structure activity relationships that resulted in the identification and subsequent preclinical and clinical development of four quinazolinone NNRTIs at the DuPont Pharmaceuticals Company...